Minerva Neurosciences to Present at 23rd Annual NewsMakers in the Biotech Industry Conference on September 9, 2016
September 02 2016 - 8:30AM
WALTHAM, Mass., Sept. 02, 2016 (GLOBE
NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a
clinical-stage biopharmaceutical company focused on the development
of innovative therapies to treat central nervous system (CNS)
disorders, today announced that it will present at the
23rd Annual NewsMakers in the Biotech Industry conference in
New York on Friday, September 9, 2016 at 1:30 p.m. eastern
time.
The presentation will be webcast and
accessible through the investor relations section of the Company's
web site, http://ir.minervaneurosciences.com.
About Minerva
Neurosciences
Minerva Neurosciences, Inc. is a
clinical-stage biopharmaceutical company focused on the development
and commercialization of a portfolio of products to treat CNS
diseases. Minerva's proprietary compounds include: MIN-101,
which has completed Phase IIb development for schizophrenia;
MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib
clinical trials in insomnia and major depressive order (MDD),
respectively; MIN-117, which has completed Phase IIa development
for MDD; and MIN-301, in pre-clinical development for Parkinson's
disease. Minerva's common stock is listed on the NASDAQ
Global Market under the symbol "NERV." For more information,
please visitwww.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Sep 2023 to Sep 2024